Jeffrey T.L. Smith's most recent trade in Zymeworks BC Inc was a trade of 17,666 Restricted Stock Unit done . Disclosure was reported to the exchange on Jan. 12, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 17,666 | 35,334 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jan 2026 | 17,666 | 36,018 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 22.67 per share. | 12 Jan 2026 | 9,310 | 26,708 (0%) | 0% | 22.7 | 211,090 | Common Stock |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 20,000 | 28,890 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2026 | 20,000 | 20,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 05 Jan 2026 | 10,538 | 18,352 (0%) | 0% | 25.1 | 264,471 | Common Stock |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 79,000 | 79,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 53,000 | 53,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 40,000 | - | - | Restricted Stock Unit | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 11,110 | 8,890 (0%) | 0% | 14.9 | 165,807 | Common Stock |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 60,000 | 60,000 | - | - | Restricted Stock Unit |